Page last updated: 2024-12-06

tetrahydrocannabivarin 9

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tetrahydrocannabivarin (THCV) is a non-psychoactive cannabinoid found in Cannabis sativa plants. It is a structural analog of tetrahydrocannabinol (THC) and has been shown to have a range of potential therapeutic benefits, including appetite suppression, anti-inflammatory properties, and potential anti-convulsant activity. THCV is thought to act as an inverse agonist at the CB1 receptor, which may explain its ability to suppress appetite and reduce THC-induced psychoactivity. THCV is also being studied for its potential to treat conditions such as obesity, diabetes, and epilepsy.'

tetrahydrocannabivarin 9: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34180
SCHEMBL ID245827
MeSH IDM0044452

Synonyms (10)

Synonym
tetrahydrocannabivarol
6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
tetrahydrocannabivarin 9
6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-propyl-
28172-17-0
SCHEMBL245827
Q254768
6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6h-dibenzo[b,d]pyran-1-ol
DTXSID50950920
9-tetrahydrocannabivarol-d5

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"We here determined pharmacokinetic profiles of the above phytocannabinoids after acute single-dose intraperitoneal and oral administration in mice and rats."( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi
Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012
)
0.38
" CBD inhibited obsessive-compulsive behaviour in a time-dependent manner matching its pharmacokinetic profile."( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi
Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.25)18.7374
1990's0 (0.00)18.2507
2000's8 (25.00)29.6817
2010's22 (68.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.93 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (15.15%)5.53%
Reviews4 (12.12%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]